Hendree E. Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hendree E. Jones has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Michelle Tuten
Department of Psychiatry and Behavioral Sciences , Johns Hopkins University School of Medicine and the Center for Addiction and Pregnancy, Johns Hopkins Bayview Medical Center , 4940 Eastern Avenue, D4 East 442, Baltimore, MD, 21224, USA
2 shared publicationsRolley E. Johnson
From the Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Md. Dr. Johnson is also employed by Reckitt Benckiser Pharmaceuticals, Inc
2 shared publicationsConrad J. Wong
1 shared publicationDace S. Svikis
Department of Psychology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, 23284, U.S.A.
1 shared publicationDace Svikis
Department of Psychology , Virginia Commonwealth University , 612 North Lombardy Street, P.O. Box 843033, Richmond, VA, 23284, USA
1 shared publicationGiao Tran
Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, U.S.A.
1 shared publication
Latest Publications
- 2 January 2008
- Published by Taylor & Francis in Journal of Maintenance in the Addictions
- Vol. 3 (2-4) , 53-64
Suicidal Ideation Among Drug-Dependent Treatment-Seeking Inner-City Pregnant Women
The current retrospective study compared the psychiatric and lifestyle characteristics of two groups of treatment-seeking pregnant, opiate and/or cocaine dependent women admitted to the Center for ...
- 2 January 2008
- Published by Taylor & Francis in Journal of Maintenance in the Addictions
- Vol. 3 (2-4) , 53-64
Suicidal Ideation Among Drug-Dependent Treatment-Seeking Inner-City Pregnant Women
The current retrospective study compared the psychiatric and lifestyle characteristics of two groups of treatment-seeking pregnant, opiate and/or cocaine dependent women admitted to the Center for ...
- 1 August 2005
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 79 (2) , 119-128
Reinforcement-based therapy: 12-month evaluation of an outpatient drug-free treatment for heroin abusers
- 1 August 2005
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 79 (2) , 119-128
Reinforcement-based therapy: 12-month evaluation of an outpatient drug-free treatment for heroin abusers
- 6 May 2005
- Published by Wiley in The American Journal on Addictions
- Vol. 14 (3) , 223-233
Males and Females Differ in Response to Opioid Agonist Medications
Few clinical trials include sex as a factor. This analysis explored within‐sex differences in response to opioid agonist medications. Males and females randomly assigned to buprenorphine, LAAM, or methadone were compared on opioid use and retention in treatment. Females receiving buprenorphine had less objective drug use than females receiving methadone, while males receiving LAAM had less objective drug use than males receiving buprenorphine. Retention in treatment was longer for both sexes receiving methadone versus LAAM. Within‐subject change results indicate that all three medications benefit both sexes. Clinical trials should be designed to examine the impact of sex on outcomes.
- 6 May 2005
- Published by Wiley in The American Journal on Addictions
- Vol. 14 (3) , 223-233
Males and Females Differ in Response to Opioid Agonist Medications
Few clinical trials include sex as a factor. This analysis explored within‐sex differences in response to opioid agonist medications. Males and females randomly assigned to buprenorphine, LAAM, or methadone were compared on opioid use and retention in treatment. Females receiving buprenorphine had less objective drug use than females receiving methadone, while males receiving LAAM had less objective drug use than males receiving buprenorphine. Retention in treatment was longer for both sexes receiving methadone versus LAAM. Within‐subject change results indicate that all three medications benefit both sexes. Clinical trials should be designed to examine the impact of sex on outcomes.
- 1 January 2003
- Published by Springer Nature in Psychopharmacology
- Vol. 165 (3) , 280-290
Oral caffeine maintenance potentiates the reinforcing and stimulant subjective effects of intravenous nicotine in cigarette smokers
Rationale. Epidemiological, clinical and pre-clinical observations suggest that caffeine can potentiate the reinforcing and discriminative effects of nicotine. Objective. The present study examined whether chronic exposure to moderate doses of caffeine affects the reinforcing and subjective effects of intravenously administered nicotine. Methods. The effects of oral caffeine maintenance on the subjective and physiological effects of intravenously administered nicotine and caffeine were examined using double-blind methods in nine volunteers with current use of tobacco, caffeine, and cocaine. Each subject was exposed to two chronic drug phases (200 mg/70 kg oral caffeine t.i.d. and placebo t.i.d.), each of at least 12 days duration. Within each drug phase, the subject received intravenous injections of placebo, nicotine (1.0 and 2.0 mg/70 kg), and caffeine (200 and 400 mg/70 kg) in mixed order. Physiological and subjective data were collected before and repeatedly after drug or placebo injection. Results. Both intravenous nicotine and caffeine produced significant increases in ratings of drug effect, stimulated, rush, and bad effect, with only nicotine significantly increasing ratings of liking and good effect. Caffeine maintenance significantly increased ratings of drug effect and stimulated after the high dose of nicotine, and significantly decreased ratings of bad effect after the low dose of nicotine. Caffeine maintenance also significantly increased the identification of the low dose of nicotine as a stimulant. A drug versus money measure of reinforcement showed that subjects were willing to pay money to receive nicotine injections, but willing to forfeit money to avoid caffeine injections. Furthermore, subjects were willing to pay significantly more money to receive the high dose of nicotine in the caffeine maintenance phase than in the abstinence phase. Both intravenous nicotine and caffeine increased diastolic blood pressure and decreased skin temperature, and nicotine also increased heart rate. These physiological effects of intravenous nicotine and caffeine as well as the subjective effects of intravenous caffeine were not influenced by caffeine maintenance. Conclusions. The results extend recent clinical and preclinical findings by showing that oral caffeine maintenance can potentiate the reinforcing and stimulant subjective effects of nicotine.
- 1 January 2003
- Published by Springer Nature in Psychopharmacology
- Vol. 165 (3) , 280-290
Oral caffeine maintenance potentiates the reinforcing and stimulant subjective effects of intravenous nicotine in cigarette smokers
Rationale. Epidemiological, clinical and pre-clinical observations suggest that caffeine can potentiate the reinforcing and discriminative effects of nicotine. Objective. The present study examined whether chronic exposure to moderate doses of caffeine affects the reinforcing and subjective effects of intravenously administered nicotine. Methods. The effects of oral caffeine maintenance on the subjective and physiological effects of intravenously administered nicotine and caffeine were examined using double-blind methods in nine volunteers with current use of tobacco, caffeine, and cocaine. Each subject was exposed to two chronic drug phases (200 mg/70 kg oral caffeine t.i.d. and placebo t.i.d.), each of at least 12 days duration. Within each drug phase, the subject received intravenous injections of placebo, nicotine (1.0 and 2.0 mg/70 kg), and caffeine (200 and 400 mg/70 kg) in mixed order. Physiological and subjective data were collected before and repeatedly after drug or placebo injection. Results. Both intravenous nicotine and caffeine produced significant increases in ratings of drug effect, stimulated, rush, and bad effect, with only nicotine significantly increasing ratings of liking and good effect. Caffeine maintenance significantly increased ratings of drug effect and stimulated after the high dose of nicotine, and significantly decreased ratings of bad effect after the low dose of nicotine. Caffeine maintenance also significantly increased the identification of the low dose of nicotine as a stimulant. A drug versus money measure of reinforcement showed that subjects were willing to pay money to receive nicotine injections, but willing to forfeit money to avoid caffeine injections. Furthermore, subjects were willing to pay significantly more money to receive the high dose of nicotine in the caffeine maintenance phase than in the abstinence phase. Both intravenous nicotine and caffeine increased diastolic blood pressure and decreased skin temperature, and nicotine also increased heart rate. These physiological effects of intravenous nicotine and caffeine as well as the subjective effects of intravenous caffeine were not influenced by caffeine maintenance. Conclusions. The results extend recent clinical and preclinical findings by showing that oral caffeine maintenance can potentiate the reinforcing and stimulant subjective effects of nicotine.
- 1 January 2002
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 37 (11) , 1411-1422
PATIENT COMPLIANCE AND MATERNAL/INFANT OUTCOMES IN PREGNANT DRUG-USING WOMEN
Treatment compliance is an important variable in drug use intervention. For pregnant drug-misusing women, compliance with treatment has been particularly problematic, even in specialized and more intensive treatment programs. The present study, conducted from March 1999 to June 2000, compared maternal/infant outcomes in pregnant drug-using women who were either compliant or noncompliant with drug use interventions offered through a prenatal care clinic. Compliant women (N = 11) completed four therapy sessions (behavioral reinforcement of drug abstinence + brief motivational therapy), while noncompliant women (N = 20) participated in zero to three therapy sessions. The two groups were similar on demographic and drug use severity measures. Compliant mothers, however, gave birth to infants with higher birthweights than noncompliant mothers. Over half of compliant mothers were also drug-free at delivery, compared to one-fourth of noncompliant mothers. These data support an association between treatment compliance and birth outcomes, and highlight the need to develop strategies for improving compliance with such interventions.
- 1 January 2002
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 37 (11) , 1411-1422
PATIENT COMPLIANCE AND MATERNAL/INFANT OUTCOMES IN PREGNANT DRUG-USING WOMEN
Treatment compliance is an important variable in drug use intervention. For pregnant drug-misusing women, compliance with treatment has been particularly problematic, even in specialized and more intensive treatment programs. The present study, conducted from March 1999 to June 2000, compared maternal/infant outcomes in pregnant drug-using women who were either compliant or noncompliant with drug use interventions offered through a prenatal care clinic. Compliant women (N = 11) completed four therapy sessions (behavioral reinforcement of drug abstinence + brief motivational therapy), while noncompliant women (N = 20) participated in zero to three therapy sessions. The two groups were similar on demographic and drug use severity measures. Compliant mothers, however, gave birth to infants with higher birthweights than noncompliant mothers. Over half of compliant mothers were also drug-free at delivery, compared to one-fourth of noncompliant mothers. These data support an association between treatment compliance and birth outcomes, and highlight the need to develop strategies for improving compliance with such interventions.
- 1 May 2001
- Published by Wolters Kluwer Health in Current Opinion in Psychiatry
- Vol. 14 (3) , 187-193
Pregnancy and substance abuse
Substance abuse/dependence are common psychiatric disorders often associated with other co-morbid diagnoses. These disorders are further complicated by pregnancy. Our knowledge of the biology, diagnosis, treatment and prevention of substance abuse/dependence during pregnancy has evolved slowly over the past few decades. The mechanistic understanding of the consequences of prenatal substance exposure, driven by preclinical data, has advanced. However, clinical research advancing the treatment of this population has been limited, remaining generally dependent on retrospective, epidemiological, and survey-type data. Only recently has prospective pharmacological research in pregnant women been advocated. In the past year, reports of mechanistic actions, the use of pharmacotherapies, long-term outcome effects, risk factors, and the effectiveness of screening and treating licit and illicit drug misuse during pregnancy have been published.
- 1 May 2001
- Published by Wolters Kluwer Health in Current Opinion in Psychiatry
- Vol. 14 (3) , 187-193
Pregnancy and substance abuse
Substance abuse/dependence are common psychiatric disorders often associated with other co-morbid diagnoses. These disorders are further complicated by pregnancy. Our knowledge of the biology, diagnosis, treatment and prevention of substance abuse/dependence during pregnancy has evolved slowly over the past few decades. The mechanistic understanding of the consequences of prenatal substance exposure, driven by preclinical data, has advanced. However, clinical research advancing the treatment of this population has been limited, remaining generally dependent on retrospective, epidemiological, and survey-type data. Only recently has prospective pharmacological research in pregnant women been advocated. In the past year, reports of mechanistic actions, the use of pharmacotherapies, long-term outcome effects, risk factors, and the effectiveness of screening and treating licit and illicit drug misuse during pregnancy have been published.
- 1 February 2001
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 61 (3) , 297-306
The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women
- 1 February 2001
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 61 (3) , 297-306
The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women